Related Experiment Videos
How to find immunomodulators--a look backward and forward.
Behring Institute Mitteilungen
|May 1, 1984
Summary
Unspecific immunomodulators show promise in lab studies but fail in human cancer trials. Broader testing in diverse disease models is crucial for predicting clinical success in cancer immunotherapy.
Area of Science:
- Immunology
- Cancer Research
- Drug Development
Background:
- Specific immunomodulation via repository adjuvants is established.
- No unspecific immunomodulator has succeeded in clinical trials for cancer patients.
- A discrepancy exists between experimental and clinical outcomes for unspecific immunomodulators.
Observation:
- Experimental immunological and tumor test systems show positive effects of unspecific immunomodulators.
- The predictive value of current screening models for clinical success is questionable.
- Unspecific immunomodulators require broader testing in ex vivo and in vivo systems.
Findings:
- Recommend comprehensive testing of compounds for immunomodulatory effects.
- Evaluate prophylactic and therapeutic potential in chronic infection, autoimmune, and inflammatory disease models.
- Screening in tumor models needs to consider minimal residual disease and metastasis.
Implications:
- Improving the success rate of unspecific immunomodulators in cancer therapy.
- Enhancing the predictive accuracy of preclinical models for clinical translation.
- Developing novel strategies for cancer immunotherapy by leveraging immunomodulatory agents.